Eosinophilic pustular folliculitis after hematopoietic stem cell transplantation: A study of 11 cases

Yu Sasaki,Akiko Kishi,Shinsuke Takagi,Naoyuki Uchida,Nobukazu Hayashi
DOI: https://doi.org/10.1111/1346-8138.15846
IF: 3.468
2021-03-14
The Journal of Dermatology
Abstract:<header class="article-table-caption"><span class="table-caption__label">TABLE 1. </span>Clinical characteristics of 11 patients with IS‐EPF after HSCT </header><table class="table article-section__table"><thead><tr><th class="bottom-bordered-cell left-aligned">Age/sex</th><th class="bottom-bordered-cell left-aligned">Graft type of HSCT</th><th class="bottom-bordered-cell left-aligned">Onset after HSCT (days)</th><th class="bottom-bordered-cell left-aligned">Underlying diseases</th><th class="bottom-bordered-cell left-aligned">Location of skin lesions</th><th class="bottom-bordered-cell left-aligned">Pruritus</th><th class="bottom-bordered-cell left-aligned">WBC (/µL)</th><th class="bottom-bordered-cell left-aligned">Eosinophils (/µL)</th><th class="bottom-bordered-cell left-aligned">Lymphocytes (/µl)</th><th class="bottom-bordered-cell left-aligned">Treatment</th><th class="bottom-bordered-cell left-aligned">Outcome</th></tr></thead><tbody><tr><td class="right-bordered-cell left-aligned">1</td><td class="left-aligned">55/F</td><td class="left-aligned">PBSC</td><td class="center-aligned">6</td><td class="left-aligned">AITL</td><td class="left-aligned">Scalp, trunk, upper and lower limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">3300</td><td class="center-aligned">297</td><td class="center-aligned">578</td><td class="left-aligned">Oral indomethacin</td><td class="left-aligned">Resolved in 8 months</td></tr><tr><td class="right-bordered-cell left-aligned">2</td><td class="left-aligned">54/M</td><td class="left-aligned">PBSC</td><td class="center-aligned">64</td><td class="left-aligned">MM</td><td class="left-aligned">Scalp, face, trunk, upper limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">4100</td><td class="center-aligned">902</td><td class="center-aligned">1210</td><td class="left-aligned">Oral indomethacin, topical steroid</td><td class="left-aligned">Resolved in 9 months</td></tr><tr><td class="right-bordered-cell left-aligned">3</td><td class="left-aligned">32/M</td><td class="left-aligned">BM</td><td class="center-aligned">44</td><td class="left-aligned">MDS</td><td class="left-aligned">Scalp, face, trunk</td><td class="left-aligned">Yes</td><td class="center-aligned">4700</td><td class="center-aligned">1410</td><td class="center-aligned">376</td><td class="left-aligned">Oral indomethacin</td><td class="left-aligned">Resolved in 2 months</td></tr><tr><td class="right-bordered-cell left-aligned">4</td><td class="left-aligned">45/M</td><td class="left-aligned">BM</td><td class="center-aligned">49</td><td class="left-aligned">MDS</td><td class="left-aligned">Trunk, upper limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">5100</td><td class="center-aligned">1071</td><td class="center-aligned">1581</td><td class="left-aligned">Oral indomethacin, topical steroid</td><td class="left-aligned">Resolved in 3 months</td></tr><tr><td class="right-bordered-cell left-aligned">5</td><td class="left-aligned">50/M</td><td class="left-aligned">BM</td><td class="center-aligned">182</td><td class="left-aligned">ALL</td><td class="left-aligned">Scalp, face, trunk, upper limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">4500</td><td class="center-aligned">428</td><td class="center-aligned">2138</td><td class="left-aligned">Topical steroid, topical indomethacin</td><td class="left-aligned">Incomplete response</td></tr><tr><td class="right-bordered-cell left-aligned">6</td><td class="left-aligned">24/M</td><td class="left-aligned">CB</td><td class="center-aligned">55</td><td class="left-aligned">AML</td><td class="left-aligned">Scalp, face, trunk, upper limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">7300</td><td class="center-aligned">4015</td><td class="center-aligned">657</td><td class="left-aligned">Oral and topical indomethacin</td><td class="left-aligned">Resolved in 2 weeks</td></tr><tr><td class="right-bordered-cell left-aligned">7</td><td class="left-aligned">25/M</td><td class="left-aligned">CB</td><td class="center-aligned">80</td><td class="left-aligned">AML</td><td class="left-aligned">Scalp, face, trunk, upper limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">10 800</td><td class="center-aligned">2646</td><td class="center-aligned">2106</td><td class="left-aligned">Oral indomethacin, topical steroid</td><td class="left-aligned">Resolved in 8 months</td></tr><tr><td class="right-bordered-cell left-aligned">8</td><td class="left-aligned">61/M</td><td class="left-aligned">CB</td><td class="center-aligned">137</td><td class="left-aligned">AA</td><td class="left-aligned">Trunk, upper and lower limbs</td><td class="left-aligned">Yes</td><td class="center-aligned">4600</td><td class="center-aligned"> <p>-Abstract Truncated-</p>
What problem does this paper attempt to address?